Cardiac resynchronisation therapy in patients with heart failure and a normal QRS duration

the RESPOND study

Paul W X Foley, Kiran Patel, Nick Irwin, John E Sanderson, Michael P Frenneaux, Russell E A Smith, Berthold Stegemann, Francisco Leyva

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

OBJECTIVES: To evaluate the clinical response to cardiac resynchronisation therapy (CRT) in patients with heart failure and a normal QRS duration (<120 ms).

SETTING: Single centre.

PATIENTS: 60 patients with heart failure and a normal QRS duration receiving optimal pharmacological treatment (OPT).

INTERVENTIONS: Patients were randomly assigned to CRT (n=29) or to a control group (OPT, n=31). Cardiovascular magnetic resonance was used in order to avoid scar at the site of left ventricular (LV) lead deployment.

MAIN OUTCOME MEASURES: The primary end point was a change in 6 min walking distance (6-MWD). Other measures included a change in quality of life scores (Minnesota Living with Heart Failure questionnaire) and New York Heart Association class.

RESULTS: In 93% of implantations, the LV lead was deployed over non-scarred myocardium. At 6 months, the 6-MWD increased with CRT compared with OPT (p<0.0001), with more patients reaching a =25% increase (51.7% vs 12.9%, p=0.0019). Compared with OPT, CRT led to an improvement in quality-of-life scores (p=0.0265) and a reduction in NYHA class (p<0.0001). The composite clinical score (survival for 6 months free of heart failure hospitalisations plus improvement by one or more NYHA class or by =25% in 6-MWD) was better in CRT than in OPT (83% vs 23%, respectively; p<0.0001). Although no differences in total or cardiovascular mortality emerged between OPT and CRT, patients receiving OPT had a higher risk of death from pump failure than patients assigned to CRT (HR=8.41, p=0.0447) after a median follow-up of 677.5 days.

CONCLUSIONS: CRT leads to an improvement in symptoms, exercise capacity and quality of life in patients with heart failure and a normal QRS duration. (ClinicalTrials.gov number, NCT00480051.).
Original languageEnglish
Pages (from-to)1041-1047
Number of pages7
JournalHeart
Volume97
Issue number13
Early online date21 Feb 2011
DOIs
Publication statusPublished - Jul 2011

Fingerprint

Cardiac Resynchronization Therapy
Heart Failure
Pharmacology
Walking
Quality of Life
Therapeutics
Cicatrix
Myocardium
Hospitalization
Magnetic Resonance Spectroscopy
Exercise
Control Groups
Survival
Mortality

Keywords

  • adult
  • aged
  • aged, 80 and over
  • cardiac resynchronization therapy
  • electrocardiography
  • epidemiologic methods
  • exercise test
  • female
  • heart failure
  • humans
  • male
  • middle aged
  • pacemaker, artificial
  • quality of life
  • treatment outcome
  • walking

Cite this

Foley, P. W. X., Patel, K., Irwin, N., Sanderson, J. E., Frenneaux, M. P., Smith, R. E. A., ... Leyva, F. (2011). Cardiac resynchronisation therapy in patients with heart failure and a normal QRS duration: the RESPOND study. Heart, 97(13), 1041-1047. https://doi.org/10.1136/hrt.2010.208355

Cardiac resynchronisation therapy in patients with heart failure and a normal QRS duration : the RESPOND study. / Foley, Paul W X; Patel, Kiran; Irwin, Nick; Sanderson, John E; Frenneaux, Michael P; Smith, Russell E A; Stegemann, Berthold; Leyva, Francisco.

In: Heart, Vol. 97, No. 13, 07.2011, p. 1041-1047.

Research output: Contribution to journalArticle

Foley, PWX, Patel, K, Irwin, N, Sanderson, JE, Frenneaux, MP, Smith, REA, Stegemann, B & Leyva, F 2011, 'Cardiac resynchronisation therapy in patients with heart failure and a normal QRS duration: the RESPOND study', Heart, vol. 97, no. 13, pp. 1041-1047. https://doi.org/10.1136/hrt.2010.208355
Foley PWX, Patel K, Irwin N, Sanderson JE, Frenneaux MP, Smith REA et al. Cardiac resynchronisation therapy in patients with heart failure and a normal QRS duration: the RESPOND study. Heart. 2011 Jul;97(13):1041-1047. https://doi.org/10.1136/hrt.2010.208355
Foley, Paul W X ; Patel, Kiran ; Irwin, Nick ; Sanderson, John E ; Frenneaux, Michael P ; Smith, Russell E A ; Stegemann, Berthold ; Leyva, Francisco. / Cardiac resynchronisation therapy in patients with heart failure and a normal QRS duration : the RESPOND study. In: Heart. 2011 ; Vol. 97, No. 13. pp. 1041-1047.
@article{7429f8d5ef1a47cf9209203841613ba5,
title = "Cardiac resynchronisation therapy in patients with heart failure and a normal QRS duration: the RESPOND study",
abstract = "OBJECTIVES: To evaluate the clinical response to cardiac resynchronisation therapy (CRT) in patients with heart failure and a normal QRS duration (<120 ms).SETTING: Single centre.PATIENTS: 60 patients with heart failure and a normal QRS duration receiving optimal pharmacological treatment (OPT).INTERVENTIONS: Patients were randomly assigned to CRT (n=29) or to a control group (OPT, n=31). Cardiovascular magnetic resonance was used in order to avoid scar at the site of left ventricular (LV) lead deployment.MAIN OUTCOME MEASURES: The primary end point was a change in 6 min walking distance (6-MWD). Other measures included a change in quality of life scores (Minnesota Living with Heart Failure questionnaire) and New York Heart Association class.RESULTS: In 93{\%} of implantations, the LV lead was deployed over non-scarred myocardium. At 6 months, the 6-MWD increased with CRT compared with OPT (p<0.0001), with more patients reaching a =25{\%} increase (51.7{\%} vs 12.9{\%}, p=0.0019). Compared with OPT, CRT led to an improvement in quality-of-life scores (p=0.0265) and a reduction in NYHA class (p<0.0001). The composite clinical score (survival for 6 months free of heart failure hospitalisations plus improvement by one or more NYHA class or by =25{\%} in 6-MWD) was better in CRT than in OPT (83{\%} vs 23{\%}, respectively; p<0.0001). Although no differences in total or cardiovascular mortality emerged between OPT and CRT, patients receiving OPT had a higher risk of death from pump failure than patients assigned to CRT (HR=8.41, p=0.0447) after a median follow-up of 677.5 days.CONCLUSIONS: CRT leads to an improvement in symptoms, exercise capacity and quality of life in patients with heart failure and a normal QRS duration. (ClinicalTrials.gov number, NCT00480051.).",
keywords = "adult, aged, aged, 80 and over, cardiac resynchronization therapy, electrocardiography, epidemiologic methods, exercise test, female, heart failure, humans, male, middle aged, pacemaker, artificial, quality of life, treatment outcome, walking",
author = "Foley, {Paul W X} and Kiran Patel and Nick Irwin and Sanderson, {John E} and Frenneaux, {Michael P} and Smith, {Russell E A} and Berthold Stegemann and Francisco Leyva",
year = "2011",
month = "7",
doi = "10.1136/hrt.2010.208355",
language = "English",
volume = "97",
pages = "1041--1047",
journal = "Heart",
issn = "1355-6037",
publisher = "BMJ Publishing Group",
number = "13",

}

TY - JOUR

T1 - Cardiac resynchronisation therapy in patients with heart failure and a normal QRS duration

T2 - the RESPOND study

AU - Foley, Paul W X

AU - Patel, Kiran

AU - Irwin, Nick

AU - Sanderson, John E

AU - Frenneaux, Michael P

AU - Smith, Russell E A

AU - Stegemann, Berthold

AU - Leyva, Francisco

PY - 2011/7

Y1 - 2011/7

N2 - OBJECTIVES: To evaluate the clinical response to cardiac resynchronisation therapy (CRT) in patients with heart failure and a normal QRS duration (<120 ms).SETTING: Single centre.PATIENTS: 60 patients with heart failure and a normal QRS duration receiving optimal pharmacological treatment (OPT).INTERVENTIONS: Patients were randomly assigned to CRT (n=29) or to a control group (OPT, n=31). Cardiovascular magnetic resonance was used in order to avoid scar at the site of left ventricular (LV) lead deployment.MAIN OUTCOME MEASURES: The primary end point was a change in 6 min walking distance (6-MWD). Other measures included a change in quality of life scores (Minnesota Living with Heart Failure questionnaire) and New York Heart Association class.RESULTS: In 93% of implantations, the LV lead was deployed over non-scarred myocardium. At 6 months, the 6-MWD increased with CRT compared with OPT (p<0.0001), with more patients reaching a =25% increase (51.7% vs 12.9%, p=0.0019). Compared with OPT, CRT led to an improvement in quality-of-life scores (p=0.0265) and a reduction in NYHA class (p<0.0001). The composite clinical score (survival for 6 months free of heart failure hospitalisations plus improvement by one or more NYHA class or by =25% in 6-MWD) was better in CRT than in OPT (83% vs 23%, respectively; p<0.0001). Although no differences in total or cardiovascular mortality emerged between OPT and CRT, patients receiving OPT had a higher risk of death from pump failure than patients assigned to CRT (HR=8.41, p=0.0447) after a median follow-up of 677.5 days.CONCLUSIONS: CRT leads to an improvement in symptoms, exercise capacity and quality of life in patients with heart failure and a normal QRS duration. (ClinicalTrials.gov number, NCT00480051.).

AB - OBJECTIVES: To evaluate the clinical response to cardiac resynchronisation therapy (CRT) in patients with heart failure and a normal QRS duration (<120 ms).SETTING: Single centre.PATIENTS: 60 patients with heart failure and a normal QRS duration receiving optimal pharmacological treatment (OPT).INTERVENTIONS: Patients were randomly assigned to CRT (n=29) or to a control group (OPT, n=31). Cardiovascular magnetic resonance was used in order to avoid scar at the site of left ventricular (LV) lead deployment.MAIN OUTCOME MEASURES: The primary end point was a change in 6 min walking distance (6-MWD). Other measures included a change in quality of life scores (Minnesota Living with Heart Failure questionnaire) and New York Heart Association class.RESULTS: In 93% of implantations, the LV lead was deployed over non-scarred myocardium. At 6 months, the 6-MWD increased with CRT compared with OPT (p<0.0001), with more patients reaching a =25% increase (51.7% vs 12.9%, p=0.0019). Compared with OPT, CRT led to an improvement in quality-of-life scores (p=0.0265) and a reduction in NYHA class (p<0.0001). The composite clinical score (survival for 6 months free of heart failure hospitalisations plus improvement by one or more NYHA class or by =25% in 6-MWD) was better in CRT than in OPT (83% vs 23%, respectively; p<0.0001). Although no differences in total or cardiovascular mortality emerged between OPT and CRT, patients receiving OPT had a higher risk of death from pump failure than patients assigned to CRT (HR=8.41, p=0.0447) after a median follow-up of 677.5 days.CONCLUSIONS: CRT leads to an improvement in symptoms, exercise capacity and quality of life in patients with heart failure and a normal QRS duration. (ClinicalTrials.gov number, NCT00480051.).

KW - adult

KW - aged

KW - aged, 80 and over

KW - cardiac resynchronization therapy

KW - electrocardiography

KW - epidemiologic methods

KW - exercise test

KW - female

KW - heart failure

KW - humans

KW - male

KW - middle aged

KW - pacemaker, artificial

KW - quality of life

KW - treatment outcome

KW - walking

U2 - 10.1136/hrt.2010.208355

DO - 10.1136/hrt.2010.208355

M3 - Article

VL - 97

SP - 1041

EP - 1047

JO - Heart

JF - Heart

SN - 1355-6037

IS - 13

ER -